Skip to main content

Table 4 Summary of structural sensitivity analysis

From: Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece

Parameter

Min ICER

Max ICER

Output differences

Treatment effect: HF only endpoints

€7,903

€9,196

€1,293

CV: mortality Kaplan Meier vs Gompertz

€9,196

€10,313

€1,117

Ivabradine treatment duration: 5 years vs lifelong

€8,145

€9,196

€1,051

NYHA extrapolation: LoCF vs Assumption based

€9,099

€9,669

€569

QoL weights: Exclude age adjustment vs include age adjustment

€9,099

€9,353

€254

CV mortality: Weibull vs Gompertz

€8,946

€9,196

€250

QoL weights: SHIFT predicted vs external literature

€8,859

€9,099

€240

NYHA extrapolation: LoCF vs SHIFT predicted

€8,966

€9,099

€133

CV mortality: exponential vs gompertz

€9,070

€9,196

€126

Titration visit and ECG costs excluded vs included

€9,077

€9,099

€22

  1. CV: cardiovascular; QoL: Quality of Life; ICER: incremental cost effectiveness ratio; HF: Heart Failure; ECG: electrocardiographic changes; NYHA: New York Heart Association; LoCF: Last observation carried forward.